Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

GlaxoSmithKline PLC (ADR) (GSK) Phase 3 Trials Looks Positive: Will Gilead Sciences, Inc. (GILD) Endure?

Efforts by GlaxoSmithKline plc (ADR) (NYSE:GSK) in carrying out a large study on its new HIV drug are yielding positive results. The Phase III trial of a dual-drug regimen was in support of the company’s confident bet that it can modify treatment orthodoxy away from three-drug combinations.

The study, which is being carried out at more than 40 sites in North and South America, Asia and Africa is incorporating 4,500 homosexual men. It will also involve transgender women who have sex with men.

Gilead GILD pharmacist store examing pharmaceutical stocks medical

kurhan /

The possible success of the trial would come at a time when GSK is also celebrating another triumph of its two-drug HIV tablet therapy, which was able to control HIV in two late-stage trials. Thus given the increasing competition in the market, the company’s current trial is likely to pose a challenge to other incumbent companies the likes of Gilead Sciences, Inc. (NASDAQ:GILD) and its three-med combos.

So Why Is This New Advance A Possible Game-Changer?

Naturally, HIV patients must continuously take their medications over their lifetime to avert a counterattack of the virus. Thus taking away one drug out of the three-med combos is one way of reducing any possible side-effect burden that patients have to bear. It is also a meant of cost saving. This is likely to hit hard on Gilead Sciences, Inc. (NASDAQ:GILD) given that it has a heavy reliance on the income from its HIV drug.

Michael Leuchten, a UBS analyst says, “The key debate remains whether Gilead Sciences, Inc. (NASDAQ:GILD) will gain the upper hand again or whether a disruptive two-drug regimen becomes standard of care, favoring GSK.”

The positive results could also a fallback for GlaxoSmithKline plc (ADR) (NYSE:GSK) in being able to defend its HIV business against any other upcoming rivals. Meanwhile, the company is testing dolutegravir in combination with generic HIV drug 3TC.

Follow Gilead Sciences Inc (NASDAQ:GILD)
Trade (NASDAQ:GILD) Now!

The Big Biotech Has A Line Of New-And-Improved Trios On The Market

The drugmaker may not have much to worry because a majority of its trios are less toxic than their predecessors. However, it is worth keeping an eye on the market. After all, everyone is working on a new establishment in an effort to outdo the other. Besides, potentially competitive regimen seems to be offering a feasible alternative. Meanwhile, GlaxoSmithKline plc (ADR) (NYSE:GSK)’s stock closed at $38.30 a decline of $0.01 or 0.03%.

Follow Glaxosmithkline Plc (NYSE:GSK)
Trade (NYSE:GSK) Now!

Note: This article is written by Andy Parker and originally published at Market Exclusive.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.